Alogliptin Tablet, Film Coated
NDC Package 11532-7002-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Alogliptin tablets is alogliptin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. This formulation utilizes a tablet, film coated delivery system. Marketed by Takeda Pharmaceutical Co Ltd, this product is identified by NDC 11532-7002.

Identification & Billing

NDC Package Code
11532-7002-1
Package Description
125000 TABLET, FILM COATED in 1 DRUM
Product Code
11532-7002
11-Digit Billing Format
11532700201

Clinical Specifications

Proprietary Name
Alogliptin
Non-Proprietary Name
Alogliptin
Substance Name
Alogliptin Benzoate
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Active Ingredient(s)
ALOGLIPTIN BENZOATE 12.5 mg/1
Usage Information
Alogliptin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Alogliptin works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.

Regulatory & Marketing

Labeler Name
Takeda Pharmaceutical Co Ltd
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
02-07-2012
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11532-7002-1 identifies a specific commercial package of 125000 tablet, film coated in 1 drum of Alogliptin (UNFINISHED drug), drug for further processing labeled by Takeda Pharmaceutical Co Ltd. This tablet, film coated is formulated for use and contains alogliptin benzoate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Takeda Pharmaceutical Co Ltd on February 07, 2012. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Alogliptin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Alogliptin works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.

How is this Takeda Pharmaceutical Co Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11532700201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
11532-7002-1
11-Digit CMS (5-4-2)
11532-7002-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.